RESTful API Testing Methodologies: Rationale, Challenges, and Solution Directions

Service-oriented architecture has evolved to be the backbone for large-scale integration between different applications and platforms. This concept has led to today's reality of cloud services. Many of the major business platforms are providing their services to end-users and other companies as well. Companies are crafting ways to allow other businesses fast service integration and to get on board quickly in the market. REST (representational state transfer) has emerged as the standard protocol for implementing and consuming these services, which are called RESTful application programming interfaces (APIs). As the internal details of the RESTful APIs are not completely available during consumption, thorough testing has been a major challenge. Any unprecedented change in the APIs can cause the major failure of service operations, which can cause an organization to face both financial and trust losses. Research efforts have been made to alleviate testing challenges by introducing different frameworks and auto-generating unit test approaches. However, there is still a lack of an overview of the state-of-the-art in RESTful API testing. As such, the objective of this article is to identify, analyze, and synthesize the studies that have been performed related to RESTful APIs' testing methodologies and unit test generation. With this perspective, a systematic literature review (SLR) study was conducted. In total, 16 papers were retrieved and included based on study selection criteria for in-depth analysis. This SLR discusses and categorizes different problems and solutions related to RESTful APIs' testing and unit test generation. 2022 by the authors. Licensee MDPI, Basel, Switzerland.Funding: This research was partially funded by the Norwegian University of Science and Technology, Norway for the support of Open Access fund.Scopus2-s2.0-8512988348

A population study of clinically actionable genetic variation affecting drug response from the Middle East

Clinical implementation of pharmacogenomics will help in personalizing drug prescriptions and alleviate the personal and financial burden due to inefficacy and adverse reactions to drugs. However, such implementation is lagging in many parts of the world, including the Middle East, mainly due to the lack of data on the distribution of actionable pharmacogenomic variation in these ethnicities. We analyzed 6,045 whole genomes from the Qatari population for the distribution of allele frequencies of 2,629 variants in 1,026 genes known to affect 559 drugs or classes of drugs. We also performed a focused analysis of genotypes or diplotypes of 15 genes affecting 46 drugs, which have guidelines for clinical implementation and predicted their phenotypic impact. The allele frequencies of 1,320 variants in 703 genes affecting 299 drugs or class of drugs were significantly different between the Qatari population and other world populations. On average, Qataris carry 3.6 actionable genotypes/diplotypes, affecting 13 drugs with guidelines for clinical implementation, and 99.5% of the individuals had at least one clinically actionable genotype/diplotype. Increased risk of simvastatin-induced myopathy could be predicted in ~32% of Qataris from the diplotypes of SLCO1B1, which is higher compared to many other populations, while fewer Qataris may need tacrolimus dosage adjustments for achieving immunosuppression based on the CYP3A5 diplotypes compared to other world populations. Distinct distribution of actionable pharmacogenomic variation was also observed among the Qatari subpopulations. Our comprehensive study of the distribution of actionable genetic variation affecting drugs in a Middle Eastern population has potential implications for preemptive pharmacogenomic implementation in the region and beyond

IMPROVING INTERNET OF THINGS NETWORK STABILITY USING A HIERARCHICAL HYPERLEDGER FABRIC MODEL

Smart contracts in the blockchain have enabled the technology to find its way beyond the financial uses in which it originally operated. As such, it has quickly found its way into the Internet of Things (IoT) networks, since the blockchain complements IoT networks by boosting its benefits (such as the modularity of the network and peer-to-peer connections). In this thesis, we aim to solve several known roadblocks that prevent the widespread adoption of blockchain technology in the IoT network; specifically, our proposed solution will be the most effective one for settings in which there is no need for all the IoT devices to communicate with each other, including smart grids, smart homes and cities, and (to a lesser extent) smart vehicles. All these models primarily have a central authority that needs a means of secure communication with its clients. Our work will make use of a hierarchical approach to the blockchain on the IoT network so that we can control the throughput that each segment uses as well as the size of the ledger. Our solution will make use of Hyperledger Fabric, which is a free and open-source blockchain framework that helps resolve the ledger size and cost issues that plague many existing solutions in the literature without compromising on the main benefits of the blockchain. As such, it enhances the integrity, authorization, and authentication of the communication among IoT devices in the network

A population study of clinically actionable genetic variation affecting drug response from the Middle East

Clinical implementation of pharmacogenomics will help in personalizing drug prescriptions and alleviate the personal and financial burden due to inefficacy and adverse reactions to drugs. However, such implementation is lagging in many parts of the world, including the Middle East, mainly due to the lack of data on the distribution of actionable pharmacogenomic variation in these ethnicities. We analyzed 6,045 whole genomes from the Qatari population for the distribution of allele frequencies of 2,629 variants in 1,026 genes known to affect 559 drugs or classes of drugs. We also performed a focused analysis of genotypes or diplotypes of 15 genes affecting 46 drugs, which have guidelines for clinical implementation and predicted their phenotypic impact. The allele frequencies of 1,320 variants in 703 genes affecting 299 drugs or class of drugs were significantly different between the Qatari population and other world populations. On average, Qataris carry 3.6 actionable genotypes/diplotypes, affecting 13 drugs with guidelines for clinical implementation, and 99.5% of the individuals had at least one clinically actionable genotype/diplotype. Increased risk of simvastatin-induced myopathy could be predicted in ~32% of Qataris from the diplotypes of SLCO1B1, which is higher compared to many other populations, while fewer Qataris may need tacrolimus dosage adjustments for achieving immunosuppression based on the CYP3A5 diplotypes compared to other world populations. Distinct distribution of actionable pharmacogenomic variation was also observed among the Qatari subpopulations. Our comprehensive study of the distribution of actionable genetic variation affecting drugs in a Middle Eastern population has potential implications for preemptive pharmacogenomic implementation in the region and beyond. 2022, The Author(s).PVJ is supported by faculty funding from the College of Health & Life Sciences, HBKU. Qatar Biobank and Qatar Genome Program are Research, Development & Innovation's entities within Qatar Foundation for Education, Science and Community Development. Funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.Scopu